ソウバギャ・スレシュ
コンサルタント
Expertise:
Sowbhagya is an Associate Consultant at EVERSANA APAC. She has more than 2 years of experience in healthcare. She has worked with several MNC clients on market entry assessments, valuation of assets in rare indications, deal negotiation strategies and opportunity assessment engagements across G7 and APAC countries.
EVERSANAに入社する前は、ディシジョン・リソーシズ・グループ、ZSアソシエイツ、サムスン・リサーチ・インスティテュートで勤務していました。ナショナル・インスティテュート・オブ・テクノロジー（NIT）ハミルプル校で工学士の学位を取得し、インド経営大学コジコデ（IIM K）でMBAを取得しています。"
Articles by ソウバギャ・スレシュ
Learning How to Play Dilution Dodgeball
The healthcare industry is reaching new heights in innovation, and as new drugs are founded, owners of biotech companies must decide whether or not they want to independently bring their product to market. Developing and successfully commercializing a biopharma product is no small undertaking. The multi-year journey is fraught with clinical, financial and operational uncertainties that many companies fail to overcome. By time the company reaches commercialization, founders usually see more than 90% reduction in equity overall. What if there was a low-risk alternative to circumvent equity dilution, allowing founders to have the best of both worlds? In today’s market – this option does exist. Download this article to learn how to play “Dilution Dodgeball” as you successfully commercialize your product and […]
Escaping the Chronic Microcap Trap: How Launching Alone Is the Only Option for Growth
As C-suite leaders in pharma wrestle with the pros and cons of launching alone, licensing or partnering with another company to launch their product, one factor they must consider is the impact their decision will have on their current and future market valuation. The question is this: How much of a premium does the market put on a company that chooses to launch and commercialize its product independently? The universe of nanocap and microcap pharma companies continues to grow, creating a backlog of companies trying to chart the course toward becoming a mid-cap or even large-cap company. Clearly, the primary means of reaching that goal is successfully launching and commercializing […]
The Chronic Microcap Trap: How Launch Is The Escape for True Growth
Pre-commercial pharma companies face a common choice: commercialize products independently or collaborate with another pharmaceutical company as a commercialization partner. As the C-suite leaders in these organizations wrestle with the pros and cons of this choice, one factor they must consider is the impact their decision will have on their current and future market valuation. The question is this: How much of a premium does the market put on a company that chooses to launch and commercialize its product independently? This white paper dives deep into the data and discusses how the average market capitalization of a cohort of public companies that developed paths to launch their own products (including […]